Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma

Cancer

Volumn 77, Issue 12, 1996, Pages 2550-2559

  Lotz, Jean Pierre ^a   Bouleuc, Carole ^a   André, Thierry ^a   Touboul, Emmanuel ^a   Macovei, Carmen ^a   Hannoun, Laurent ^b   Lefranc, Jean Pierre ^c   Houry, Sidney ^a   Uzan, Serge ^c   Izrael, Victor ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

autologous stem cell transplantation; carboplatin; high dose chemotherapy; ovarian carcinoma

Indexed keywords

CARBOPLATIN; IFOSFAMIDE; TENIPOSIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARBOPLATIN; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TENIPOSIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 9344222252     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2550::AID-CNCR19>3.0.CO;2-R     Document Type: Article

References (61)

1. Richardson GS, Scully RE, Najamosama N, Nelson JH. Common epithelial cancer of the ovary (first of two parts). New Engl J Med 1985;312:415-24.
2. Richardson GS, Scully RE, Najamosama N, Nelson JH. Common epithelial cancer of the ovary (second of two parts). New Engl J Med 1985;312:474-83.
3. Thigpen JT. Chemotherapy in the management of celomic epithelial carcinoma of the ovary. In: Markman M, Hoskins WJ, Editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:277-86.
4. McGuire WP. Experimental agents (non biological) in ovarian cancer. In: Markman M, Hoskins WJ, Editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:287-300.
5. Hakes TB. Prognostic factors in ovarian cancer. In: Markman M, Hoskins WJ, Editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:115-26.
6. Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In: De Vita VT Jr., Hellman S, Rosenberg SA, Editors. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: Lippincott, 1993:1226-63.
7. Van Houwelingen JC, Ten Bokkel Huinink WW, Van der Burg MEL, Van Oosterom AT, Neijt JP. Predictibility of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989;7:769-73.
8. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian cancer. Obstet Gynecol 1992;80:954-60.
9. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
10. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partdrige EE, Look KY, et al. Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin [abstract]. Proc Am Soc Clin Oncol 1995;14:275.
11. Jänicke F, Hölscher M, Kuhn W, Von Hugo R, Pache L, Siewert JR, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
12. Caldas C, McGuire WP. Taxol in epithelial ovarian cancer. Monogr Natl Cancer Inst 1993;15:155-9.
13. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman DA, Fisherman JS, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405-10.
14. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
15. Mychalczak BR, Fuks Z. The role of radiotherapy in the management of epithelial ovarian cancer. In: Markman M, Hoskins WJ, Editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:229-41.
16. Markman M. Intraperitoneal chemotherapy. In: Markman M, Hoskins WJ, Editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:317-25.
17. King LA, Downey GO, Polish RA, Adcock LL, Carson LF, Twiggs LB. Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. Cancer 1991;67:2867-71.
18. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
19. Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Autologous bone marrow transplantation. Current studies and future directions. Ann Intern Med 1989;110:51-65.
20. Frei E, Antman K, Teicher B, Eder JP, Schnipper L. Bone marrow autotransplantation for solid tumors: prospects. J Clin Oncol 1989;7:515-26.
21. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, et al. Phase I and II study of high dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 1992;10:1712-22.
22. Lotz JP, Machover D, Malassagne B, Hingh B, Donsimoni R, Gumus Y, et al. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 1991;10:1860-70.
23. Lotz JP, André T, Donsimoni R, Firmin C, Bouleuc C, Bonnak H, et al. High-dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995;75:874-85.
24. Radice PA, Bunn PA, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 1979;63:1231-9.
25. De Vries EGE, Mulder NH, Postmus PE, Vriesendorp R, Willemse PHB, Sleijfer DT. High-dose teniposide for refractory malignancies: a phase I study. Cancer Treat Rep 1986; 70:595-8.
26. Holthuis J, De Vries EGE, Postmus PE, Van Oort WWJ, Verleun H, Hulshoff A, et al. Pharmacokinetics of high-dose teniposide. Cancer Treat Rep 1987;71:599-604.
27. Thigpen JT, Lambuth BW, Vance RB. The role of ifosfamide in gynecologic cancer. Semin Oncol 1992;19(Suppl 1):30-4.
28. Markman M, Hakes T, Reichman B, Lewis JL, Rubin S, Jones W, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10:243-8.
29. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81:1467-71.
30. Brade WP, Herdrich K, Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12:1-47.
31. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 1990;17(Suppl 4):68-73.
32. Ozols RF, Ostchega Y, Curt G, Young RC. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987;5:197-201.
33. Bishop JF. Current experience with high-dose carboplatin therapy. Semin Oncol 1992;19:150-4.
34. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, et al. A phase I clinical and pharmacological study of carboplatin and autologous bone marrow support. J Clin Oncol 1989;7:651-61.
35. International Federation of Gynecology and Obstetrics. Changes in definition of clinical stages for carcinoma of the cervix and the ovary. Am J Obstet Gynecol 1987;156:236-41.
36. Miller AB, Hoogstraten B, Staquet M, Winckler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
37. Nemunaitis J. Use of hematopoietic growth factors in marrow transplantation. Curr Opin Oncol 1994;6:139-45.
38. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. JASA 1958;53:457-81.
39. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-67.
40. Levin L, Simon R, Hryniuk WM. Importance of multiagent chemotherapy regimens in ovarian carcinomas: dose intensity analysis. J Natl Cancer Inst 1993;85:1732-42.
41. Ozols RF, Behrens BC, Ostchega Y, Young RC. High-dose cisplatin and high-dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985;12(Suppl A):59-65.
42. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic salin in refractory ovarian cancer. J Clin Oncol 1985;3:1246-50.
43. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987;71:127-30.
44. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cisdiamminedichloroplatinum (II) therapy. Cancer Res 1987;47: 1457-60.
45. Quezado ZMN, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6.
46. Van der Gaast A, Splinter TAW. Teniposide (VM-26) in ovarian cancer: a review. Semin Oncol 1992;19(Suppl 6):95-7.
47. Muggia FM, Groshen S, Russel C, Jeffers S, Chen SC, Schlaerth J, et al. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimen. Gynecol Oncol 1993;50:232-8.
48. Markman M, Blessing JA, Major F, Manetta A. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: A Gynecologic Oncology Group study. Gynecol Oncol 1993;50:191-5.
49. Seymour MT, Mansi JL, Gallagher CJ, Gore ME, Harper PG, Evans TRJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-5.
50. Mulder POM, Willemse PHB, Aalders JG, De Vries EGE, Sleijfer DTH, Cibinga CTS, et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur Cancer Clin Oncol 1989; 25:645-9.
51. Dauplat J, Legros M, Condat P, Fernere JP, Ben Ahmed S, Plagne R. High-dose melphalan with autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989;34:294-8.
52. Viens P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, et al. High-dose melphalan with autologous bone marrow rescue in advanced ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990;5:227-33.
53. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990;38:386-91.
54. Benedetti Panici P, Scambia G, Baiocchi G, Greggi S, Battaglia F, Salerno G, et al. High-dose chemotherapy and autologous peripheral stem cell (APSC) support in advanced ovarian cancer (AOC) [abstract]. Proc Am Assoc Clin Oncol 1991;10:195.
55. Broun ER, Belinson JL, Berek JS, McIntosh D, Hurd D, Ball H, et al. Salvage therapy for recurrent and refractory ovarian cancer high-dose chemotherapy with autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1994;54:142-6.
56. Murakami M, Shinozuka T, Kuroshima Y, Tokuda Y, Tajima T. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Semin Oncol 1994;21(Suppl 1):29-32.
57. Stiff PJ, McKenzie S, Alberts DS, Sosman JA, Dolan JR, Rad N, et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 1994;12:176-83.
58. Stiff P, Bayer R, Sosman J, Peace D, Dolan J, Potkul R. Platinum sensitivity and low tumor burden are of prognostic significance in patients undergoing an autologous bone marrow transplant (ABMT) for advanced ovarian cancer [abstract]. Proc Am Assoc Clin Oncol 1995;14:268.
59. Shpall EJ, Stemmer SM, Bearman SI, Bast RC, Peters WP, Ross M, et al. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Markman M, Hoskins WJ, editors. Cancer of the ovary. New York: Raven Press Ltd., 1993:327-38.
60. Fennelly D, Schneider J, Spriggs D, Bengale C, Hakes T, Reich L, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995;13:1160-6.
61. Ross AA, Miller GW, Moss TJ, Kahn DG, Warner KE, Sweet DL, et al. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Bone Marrow Transplant 1995;15:929-33.